Research
Hormonal
Consumption of probiotic yoghurt containing specific strains (L. acidophilus La5 and B. lactis Bb12) improves glycemic control (fasting blood sugar, HbA1c) and lipid profiles in patients with Type 2 Diabetes.
If you have Type 2 Diabetes, incorporating 300g of probiotic yoghurt daily (specifically with L. acidophilus La5 and B. lactis Bb12) may help lower blood sugar and cholesterol levels. Consult your doctor before making dietary changes.
GoodSupportsHIGH confidence
Consuming probiotic yoghurt helped type 2 diabetic patients have lower fasting blood sugar and hemoglobin A1c levels and better antioxidant status [60]. Moreover, the consumption of probiotic yoghurt reduced total cholesterol and LDL cholesterol levels in type 2 diabetics
Why this rating
Supported by randomized controlled trials showing specific metabolic improvements.
Source
Beneficial Effects of Yoghurts and Probiotic Fermented Milks and Their Functional Food Potential
Elena Hadjimbei et al. · Foods · 2022
DOI 10.3390/foods11172691
narrative_reviewCited 180×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Consumption of yoghurt and fermented milk products is associated with reduced cardiovascular disease risk factors, including lower total cholesterol, LDL cholesterol, triglycerides, and blood pressure.Strong
- Consumption of probiotic fermented milks and yoghurts is associated with improved bone mineral density (BMD) and a significantly reduced risk of osteoporosis and osteopenia, particularly in females.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →